(Q39540970)

12 September 2017

title

Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service (English)

1 reference

12 September 2017

1

1 reference

12 September 2017

Lewis M

2

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

12 September 2017

1 reference

12 September 2017

volume

15

1 reference

12 September 2017

issue

3

1 reference

12 September 2017

page(s)

220-226

1 reference

Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Antipsychotic drug doses in a schizophrenia inpatient unit

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

The Hampstead Schizophrenia Survey 1991. I: Prevalence and service use comparisons in an inner London health authority, 1986-1991.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Neuroleptic dose and schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Changing patterns of neuroleptic dosage over a decade.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

Pharmaco-epidemiology in 136 hospitalized schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900222-4

7 January 2021

10.1016/S0924-9338(00)00222-4

Identifiers

DOI

1 reference

release_x3zscbj2rjennm4bmhmxbxpvxa

12 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x3zscbj2rjennm4bmhmxbxpvxa

24 November 2022

mapped directly with Wikidata item

1 reference